C-MNY7Deep Origin
physics-based AI, molecular modeling, drug discovery
discoverydiscoveringsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-MNY7
C-MNY7C-MNY7physics-based AI, molecular modeling, drug discovery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Formic Ventures | Portfolio, Investments & AUM | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Investors Formic Ventures Formic Ventures San Francisco, California formic.vc Overview Formic Ventures is a diversified venture capital firm that makes early-stage investments in biotechnology startups focused on human longevity, as well as technology startups and companies that make human lives more meaningful. The firm prefers to invest in seed-stage and early-stage companies operating in the biotechnology, artif
Deep Origin Promotes Natalie Ma To Chief Business Officer | Let's Data Science Skip to content LDS Let's Data Science LEARN • BUILD • STAY AHEAD News Blog Learn Code Problems Pricing Contact Sign in © 2026 Let's Data Science Advertise | Terms | Privacy | Cookie preferences | Image Rights Feedback News Deep Origin Promotes Natalie Ma To Chief Business Officer Industry News computational drug discovery executive hire deep origin Deep Origin Promotes Natalie Ma To Chief Business Officer 1 sources | March 17, 2026 2.8 Relevance Score Photo: cdnx.premiumread.com · rights & takedo
Rho | Top Medical Device VC Firms 2026 Products Business Checking Enjoy $0 ACH fees and up to $75M FDIC insurance. Business Savings Protect and grow your cash in one place. Treasury Earn 4.42% on your idle cash. Corporate Cards Earn up to 1.5% cash back on all spend with Rho cards. Expense Management Eliminate expense reports and capture every receipt. Bill Pay Pay hundreds of vendors in minutes with zero fees. Invoicing Send invoices and get paid from where you bank. Capital Apply in minutes. Funds land directly in your Rho account. Close Close your books faster, every month SAFE Note Generat … th zero fees. Invoicing Send invoices and get paid from where you bank. Capital Apply in minutes. Funds land directly in your Rho account. Close Close your books faster, every month SAFE Note Generator Generate a SAFE note in minutes Solutions Rho for Startups Manage cash, limit burn, and automate finances. Rho for Small Businesses Manage your company cash, track expenses, and simplify accounting. Rho for Enterprises Streamline accounting and expenses across multiple entities … iomedicines. Their model includes both direct venture capital investments and a fund of funds strategy. This firm is a strong match for founders with a deep-tech or AI-centric business. Their multi-stage approach is ideal for teams seeking a long-term financial partner to support their growth. Once funding is secured, Rho’s integrated financial tools — including business banking, corporate cards, and automated bill pay — help startups manage and deploy capital efficiently. In … roq, Glyphic Biotechnologies, March Biosciences Investor type: Venture Capital, Fund of Funds You can refer to their website here . 10. HLM Venture Partners HLM Venture Partners is a Boston-based venture capital firm that has been investing in healthcare technology companies since 1983. They focus on businesses in health care, information technology, and the medical device sector. The firm is notable for its flexible, multi-stage investment approach, supporting companies from
SmartGateVC | Portfolio Portfolio Team Founder Resources Highlights Careers Portfolio We build a family. Our portfolio companies define categories across AI Infrastructure & Physical AI, Robotics, Cybersecurity, Neurotech & Brain-Computer Interfaces SuperAnnotate: AI data platform for end-to-end model building SuperAnnotate bridges the gap between cutting-edge AI innovation and the high-quality human data that powers it - helping advanced AI teams build more intelligent models. SuperAnnotate powers complex annotation, evaluation, and reinforcement learning workflows to build, evaluate, … Applications (Gartner) The 100 BestInventions Of 2020 (TIME) Golden Kitty 2018 Award (Product Hunt) Mashable, TechCrunch, NVIDIA, Intel, BBC News, Washington Post SuperAnnotate: The fastest annotation platform and services for training AI $14.5M Series A with Base10 Partners, Point Nine Capital, Runa Capital, Fathom Capital Among Top 100 most promising private AI companies in the world in 2021 (CBInsights AI 100) Strategic Partnership With OpenCV to Improve Annotation for Co … t more accessible $7M Series A with Point Nine, RTP Global, Sierra Ventures, AI Fund #1 Product of 15.08.2020 on Product Hunt Business Insider, Yahoo News, The Next Web, Adweek, Diginomica, TechCrunch 7 Must Have Chrome Extensions for Marketers Activeloop (formerly Snark AI): Having Amazon/Google quality AI models at your disposal 24/7 $5M Seed with 468 Capital, CM Venture, Shasta Ventures, Tribe Capital YC S18 batch TechCrunch Biosim AI: Enabling and accelerating drug discov … ateVC LLC Designed with love by [email protected] © 2017-2026 by SmartGate Seed Fund I Partners, LLC
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
has not parsed yet. --> Tim Foley - Chief Commercial Officer | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Start a trial → Out-licensing Asset Co-De
has not parsed yet. --> Jason Sunardi - Commercial and Strategy Associate | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Start a trial → Out-licensin
Expired: Scientist, Computational Chemistry at Deep Origin | Sorce Jobs Deep Origin Posted 1 month ago EXPIRED Scientist, Computational Chemistry Deep Origin Posted 1 month ago Remote EXPIRED Remote Full Time Mid Level Doctorate Or Professional Degree Full Time Mid Level Doctorate Or Professional Degree Job Summary Deep Origin seeks a Scientist in Computational Chemistry to support a transformative ARPA-H initiative, involving molecular dynamics simulations and machine learning for therapeutic discovery. Responsibilities include designing simulation workflows and analyzing protein-ligand inter … ponsorship of an employment Visa Scan for similar Find similar roles on Sorce → Apply to this job in one click with Sorce Find similar roles → Tinder for jobs Email Twitter LinkedIn Instagram TikTok Employers/Post Job Passport Case studies Blog T&C Privacy Security Twitter Instagram LinkedIn TikTok Email Employers/Post Job Mobile App Blog T&C Privacy Security
Tim Foley Joins Deep Origin as Chief Commercial Officer | Deep Origin | F. Matthew Bakthasekaran, MBA LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agre
Natalie Ma - Deep Origin | Biotech Showcase Speaker You need to enable JavaScript to run this app. The premier investor event January 11–13, 2027 | San Francisco, CA January 19–20, 2027 | Digital Partnering Home home About the event expand_more Biotech Showcase Get event brochure Who attends Attend expand_more Registration Options Present expand_more Company Presentation Options Presenter Resource Center Program expand_more Program Highlights 2026 Agenda 2026 Speakers partneringONE expand_more Partnering Partnering Upgrades Sponsors expand_more Sponsorship Brochure Sponsors Plan & Prepare
Deep Origin San Francisco Jobs + Careers | Built In San Francisco San Francisco Global Tech Hub BuiltIn.com is the global destination for tech professionals. builtin.com Popular Tech Hubs United States Austin Boston Chicago Colorado Los Angeles New York City Seattle San Francisco Australia Sydney Melbourne Canada Calgary Montreal Ottawa Quebec Toronto Vancouver India Bengaluru Chennai Delhi Hyderabad Kolkata Mumbai Pune Ireland Dublin Singapore Singapore United Kingdom London Cambridge Manchester Birmingham Bristol Companies Jobs Articles Can't find your company? Create a company profile.
UK Agency ARIA Funds AI and Robotic Lab Collaboration to Discover Novel Endometriosis Therapy in Under Nine Months | Femtech Insider Latest News Menstrual Health Reproductive Health Fertility Pregnancy Maternal Health Menopause Hormonal Health Mental Health Gynecological Health Endometriosis Chronic Conditions Sexual Wellness Heart Disease Pelvic Health Bone Health Cancer Newsletter Jobs Events UK Agency ARIA Funds AI and Robotic Lab Collaboration to Discover Novel Endometriosis Therapy in Under Nine Months By Femtech Insider Endometriosis , News , Partnership March 26, 2026 Share Twitter Face … ’s Advanced Research & Invention Agency (ARIA) has awarded a £500,000 grant to fund a collaboration between San Francisco-based Deep Origin and Oxford-based Arctoris with an ambitious goal: identify a novel drug target and a validated molecule for endometriosis by the end of the year – compressing a process that traditionally takes a decade into less than nine months. The project, called “Silico Habilis,” is part of ARIA’s AI Scientist progra
Deep Origin Congratulates Isomorphic Labs on Catching Up | The Na Skip to main content June 26, 2026 Volume XVI, Number 177 Legal Analysis. Expertly Written. Quickly Found. Login Publish / Advertise Publish Advertise Publishing Firms NLR Newsletters Contact Us Terms of Use Privacy Policy About Contact Us NLR Team Publishing Firms NLR Newsletters NLR Thought Leadership Awards 2018 2019 2020 2021 2022 Terms of Use Privacy Policy Quick Links Type of Law Antitrust Law Artificial Intelligence Law News Bankruptcy & Restructuring Biotech, Food & Drug Business of Law Construction & Real Es
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Ashot Papoyan Advances Biotech in US and Armenia - The Armenian Mirror-Spectator TOP STORIES WEEK 26 Armenia & Karabakh Arts & Culture Opinion Community International Genocide Recipes More Videos Calendar Subscribe Archives Past Issues About Us Contact Us or Donate Search Sign in Welcome! Log into your account your username your password Forgot your password? Get help Password recovery Recover your password your email A password will be e-mailed to you. The Armenian Mirror-Spectator Top Stories Most read stories of the month 26 Week Latest articles of the week Ar … hymena thermophila , a single-celled organism. In 2011, Tetragenetics secured a grant from the state of Massachusetts to relocate to Cambridge and later to Arlington. The company was ultimately acquired by AbCellera Biologics, a Vancouver-based biotech firm. In 2019 Papoyan founded a new company, Elm Tree Research , together with Dr. Zorayr Manukyan, to focus on research and clinical trial design, execution and data utilization to provide effective treatment for addictions. T … rants to Armenian scientists through the Armenia National Science and Education Fund (ANSEF), founded by Cornell astrophysicist Professor Yervant Terzian. Proposals are sent from Armenia to peers in America for review, and the highest scored innovations receive grants. ANSEF is part of the Fund for Armenian Relief (FAR), which is the umbrella organization of the Eastern Diocese of the Armenian Church of American for philanthropy to Armenia. Currently, he is the co-chair of AN
has not parsed yet. --> We're Leading an Up to $31.7M ARPA-H Contract Award to Build In-Silico Models To Replace Animal Testing | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capabil … n Login Resources / News News We're Leading an Up to $31.7M ARPA-H Contract Award to Build In-Silico Models To Replace Animal Testing The Deep Origin Team December 4, 2025 We’re thrilled to share that Deep Origin and our partners in the Pharmacological Research and Evaluation through Digital Integration and Clinical Trial Simulation (PREDICTS) consortium have been awarded an up to $31.7 million contract from the Advanced Research Projects Agency for Health (ARPA-H) Comput … s, reach out to us here . While we have selected ex vivo models for our initial proposal, there is a ton of complex human biology to capture as we build a comprehensive virtual human model. If you’re a drug developer , you can already explore early versions of our models in Balto or reach out for early access . Together, we can shape a future where drug development is faster, more successful, and no longer dependent on animal testing. If you want to join the cause, reach out
has not parsed yet. --> Gor Lavchyan - Head of Global Operations | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Start a trial → Out-licensing Asset C
Deep Origin Jobs | Levels.fyi Download App Login Sign Up All Data By Location By Company By Title Salary Calculator Chart Visualizations Verified Salaries Internships H-1B Salaries Negotiation Support Compare Benefits Who's Hiring 2025 Pay Report Top Paying Companies Integrate Blog Press Google Software Engineer Product Manager New York City Area Data Scientist Explore By Different Titles Levels FYI Logo Salaries 📂 All Data 🌎 By Location 🏢 By Company 🖋 By Title 🏭️ By Industry 📍 Salary Heatmap 📈 Chart Visualizations 🗺️ Atlas 🔥 Real-time Percentiles 🎓 Internships 🛂 H-1B Salaries
Balto FAQs | Deep Origin documentation Skip to main content Documentation Support and feedback Policies Balto Balto FAQs DO Studio DO Patent User accounts Organizations Billing and payment Support and feedback Policies Balto Balto FAQs On this page Balto FAQs General Information What is Balto? Balto is a generative AI solution for Drug Discovery enthusiasts. It uses a chat interface to communicate with users in plain English and solve key drug discovery problems: find information about ligands and proteins find novel pockets on a protein surface use the proprietary docking method to simula
has not parsed yet. --> Terms of Service | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Start a trial → Out-licensing Asset Co-Development Selected a … or use of Third-Party Content." 9. Mobile Features Deep Origin may offer mobile application or website features including uploading content, receiving messages, downloading applications, or accessing features on mobile phones. Standard messaging, data, and other fees may apply per carrier. Carriers may prohibit or restrict features, and some may be incompatible. By using mobile features, users agree Deep Origin may send communications and collect device information per the Pr … Users are solely responsible for creating backup copies at their cost. License Grant Unless a signed written agreement states otherwise, "if you submit, transmit, display, post, or store User Content using the Services, you grant Deep Origin and its sub-licensees, to the furthest extent and for the maximum duration permitted by applicable law an unrestricted, worldwide, irrevocable, fully sub-licenseable, nonexclusive, and royalty-free right to use, reproduce, modify, adapt, … create, own, or control all User Content rights or have sufficient authority to grant stated rights; (b) User Content does not infringe third-party rights including "copyright, trademark, patent, trade secret, moral right, privacy right, right of publicity, or any other intellectual property or proprietary right"; and (c) User Content contains no viruses, adware, spyware, worms, or harmful code. Deep Origin reserves rights and remedies against breaching users. Unauthorized Us … t. "Except as expressly and unambiguously provided herein, Deep Origin does not grant you any express or implied rights in or to the Services; all rights in and to the Services are retained by us." "Content and Materials provided on or through the Services is provided to you 'AS IS,' 'WITH ALL FAULTS,' and 'AS AVAILABLE' for your informational an
has not parsed yet. --> Garik Petrosyan - Head of AI | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Start a trial → Out-licensing Asset Co-Developmen
has not parsed yet. --> AI-Powered Drug Discovery Platform | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Start a trial → Out-licensing Asset Co-Deve … ty years of peer-reviewed research in molecular physics underpins the models we apply to pharma programs. LinkedIn → Learn about Deep Origin Latest Resources Insights from our team on drug discovery, computational chemistry, and scientific innovation. View all resources Blog Post Finding Promising Molecules and Biological Background With Balto Read article Company News Can AI Shrink the Drug Development Timelines for Endometriosis? Company News We Built a 98% Accurate Fu
Deep Origin Wins $31.7M ARPA-H Contract for In-Silico Safety Models | SmartGateVC posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign i … ap starting with monoclonal antibodies. In July, the NIH said it will no longer fund projects that rely only on animals. In November, the CDC announced it will end all monkey research by the end of 2025, affecting about 200 macaques. This is the first time a U.S. agency has shut down its primate program since NIH retired chimps a decade ago. We’re not saying animal models are useless. They’ve been essential for decades and we acknowledge that. The point is that for many appli
Press Release Distribution and Management Accessibility: Skip TopNav Latest News and Press Releases Want to stay updated on the latest news? Sign into Reader Account Create Reader Account March 31, 2026 08:00 ET | Source: Deep Origin Tim Foley Joins Deep Origin as Chief Commercial Officer Deep Origin announced today that Tim Foley has joined the company as Chief Commercial Officer. March 17, 2026 08:00 ET | Source: Deep Origin Deep Origin Promotes Natalie Ma, PhD, to Chief Business Officer as Company Advances Computational Drug Discovery Platform Deep Origin announced the promotion of N
Deep Origin & Arctoris Selected for ARIA AI Scientist Program to Accelerate Endometriosis Research | Deep Origin posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By … integration between computation and high-fidelity experimental data. This ARIA award accelerates a strategic step we already lead: coupling rigorous, high-fidelity automation with production-grade AI. Together we will validate AI-generated hypotheses faster and more reproducibly, compressing discovery timelines and improving decision quality. ARIA creates the opportunity to close the loop between model and experiment at scale. By combining Deep Origin’s computational drug di … e, AI-ready wet lab datasets designed to power modern discovery workflows. This award recognises the commercial and scientific value of tightly integrated automation and AI, and sets a new benchmark for autonomous discovery. Excited to build this future together. #ARIA #AIScientist #EndometriosisResearch #DrugDiscovery #AutonomousLabs #BiotechInnovation #Arctoris 17 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Arctoris 8,752 followers 4mo Edit … integration between computation and high-fidelity experimental data. This ARIA award accelerates a strategic step we already lead: coupling rigorous, high-fidelity automation with production-grade AI. Together we will validate AI-generated hypotheses faster and more reproducibly, compressing discovery timelines and improving decision quality. ARIA creates the opportunity to close the loop between model and experiment at scale. By combining Deep Origin’s computational drug di … e, AI-ready wet lab datasets designed to power modern discovery workflows. This award recognises the commercial and scientific value of tightly integrated automation and AI, and sets a new benchmark for autonomous discovery. Excited to build this future together. #ARIA #AIScientist #EndometriosisResearch #DrugDiscovery #AutonomousLabs #BiotechInn
has not parsed yet. --> Resources | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Start a trial → Out-licensing Asset Co-Development Selected assets f … r 9, 2025 News • Company News We're Leading an Up to $31.7M ARPA-H Contract Award to Build In-Silico Models To Replace Animal Testing Updated: December 4, 2025 Scientific poster • Drug discovery Accelerating Drug Discovery with Physics-Informed Machine Learning Updated: November 11, 2025 Press mention • Company News Deep Origin Partners with AccuKnox for Cloud Security Updated: October 17, 2025 Blog • Trends Out-of-the-Box GenAI for Medicinal Chemistry Updated: December 1
has not parsed yet. --> Deep Origin Promotes Natalie Ma, PhD, to Chief Business Officer as Company Advances Computational Drug Discovery Platform | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computa … s and in our work to develop more predictive drug safety models on our CATALYST award from ARPA-H. I’m excited to see what researchers globally can do in drug design with DODock,” said Natalie Ma. Mostafa Ahmed, PhD, Joins as Senior Principal Scientist Deep Origin has also welcomed Mostafa Ahmed as Senior Principal Scientist, where he will focus on advancing the company’s prospective drug discovery efforts and deepening partnerships with biotech and pharmaceutical companies. … from benchmark performance to real-world results with partners. His ability to apply computational tools to drug programs will strengthen all of our collaborations,” said Garegin Papoian, PhD, Co-Founder and Chief Scientific Officer. About Deep Origin Deep Origin is a computational drug discovery company working to replace uncertainty with computational precision in small molecule drug discovery and development. Co-founded by Michael Antonov, co-founder of Oculus, and Garegi … Catching Up February 11, 2026 We're Leading an Up to $31.7M ARPA-H Contract Award to Build In-Silico Models To Replace Animal Testing December 4, 2025 6000 Shoreline Ct. Ste 325, South San Francisco, CA 94080. © 2023-2026 Deep Origin Inc. All rights reserved. Deep Origin is a registered trademark of Deep Origin Inc. Newsletter | Events and Webinars | CompChem Glossary | Documentation | Support | Company News Master Services Agreement | Subscriber Credits Addendum | S
has not parsed yet. --> Natalie Ma - Chief Business Officer | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Start a trial → Out-licensing Asset Co-Dev
Deep Origin Partners With AccuKnox For Cloud Security » Accuknox --> SEARCH Platform Unified Zero Trust CNAPP Continuous Compliance Compliance Features Governance, Risk, Compliance (GRC) Cloud Compliance Workload Compliance AI Compliance API Compliance Secure Cloud CloudSec Features Asset Inventory Misconfigurations & Drift Detection Cloud Detection and Response (CDR) Cloud Compliances Linux/Windows Scanning K8s Risk Assessment Serverless & Fargate Secure Code AppSec Features Static Application Security Testing (SAST) Dynamic Application Security Testing (DAST) Software Composition Analy … indows Scanning K8s Risk Assessment Serverless & Fargate AppSec Features Static Application Security Testing (SAST) Dynamic Application Security Testing (DAST) Software Composition Analysis (SCA) Software Bill of Materials (SBOM) Container Scanning CI/CD Pipeline Security Secret Scanning IaC Scanning AI-Accelerated SAST Scanning WorkloadSec Features Admission Controller Security Container and VM Forensics Zero Trust Runtime Security Threat Detection Microsegmentation Vulnerab … 5, 2024 – AccuKnox, Inc. , a leading provider of Zero Trust CNAPP (Cloud Native Application Protection Platform), announced that Deep Origin forged a partnership to secure Cloud Application, LLM/ML Models and Jupyter Notebook workloads on AWS. AccuKnox delivers Zero Trust Cloud Security that secures “Code to Cloud” and delivers “Build to Run-time” Security. AccuKnox is an integrated platform that is made up of the following modules: ASPM (Application Security Posture Man … erability Management & Prioritization Run-time security, Micro-segmentation Application Firewalling, Kernel Hardening Drift Detection & Audit Trail Continuous Diagnostics & Mitigation GRC – CIS, HIPAA, GDPR, SOC2, STIG, MITRE, NIST compliance Securing Mission-Critical Workloads like Vault Securing AI workbenches like Jupyter Notebooks AccuKnox CNAPP offers the following Key Differentiators Inline Security (as opposed to Post-attack security) Secures modern workloa
has not parsed yet. --> Matt Shlosberg - COO | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Start a trial → Out-licensing Asset Co-Development Select
has not parsed yet. --> Tim Foley Joins Deep Origin as Chief Commercial Officer | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Start a trial → Out-li … Catching Up February 11, 2026 We're Leading an Up to $31.7M ARPA-H Contract Award to Build In-Silico Models To Replace Animal Testing December 4, 2025 6000 Shoreline Ct. Ste 325, South San Francisco, CA 94080. © 2023-2026 Deep Origin Inc. All rights reserved. Deep Origin is a registered trademark of Deep Origin Inc. Newsletter | Events and Webinars | CompChem Glossary | Documentation | Support | Company News Master Services Agreement | Subscriber Credits Addendum | S
has not parsed yet. --> Software Licensing Agreement | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Start a trial → Out-licensing Asset Co-Developmen … lities to the Software that is not included in a Software Update 2. License 2.1 Grant of License to the Software. Subject to this Agreement, Deep Origin grants Subscriber, and its Authorized Persons (collectively referred to herein, as the Subscriber), a non-exclusive, non-transferable, revocable, limited right and license to access and use the Software (the "License"), by accessing the Deep Origin Platform. 2.2 Subscriber Access to Deep Origin Software. In order to access th … c) it has the full right, power, and authority to enter into this Agreement, to grant Subscriber the rights and Licenses set forth herein, and to perform its obligations hereunder; (d) the execution of this Agreement and the delivery of this Agreement by Deep Origin have been duly authorized by all necessary action on the part of Deep Origin; and (e) it has the full right, power, and authority (by ownership, license, or otherwise) to use all Intellectual Property Rights embod … erwise) to use all Intellectual Property Rights embodied in the Software and to grant Subscriber the rights and licenses set forth herein on the terms and conditions of this Agreement. 4. Representations and Warranties of the Subscriber Subscriber represents and warrants to Deep Origin that: (a) neither Subscriber, nor any of the Authorized Persons permitted access to the Software, are a competitor of Deep Origin, nor affiliated directly or indirectly with a competitor of Dee … n a separate written contract; (l) Use any robot, spider, site search/retrieval application, or other automated device, process or means to access, retrieve, scrape, or index any portion of the Software or any related content; (m) Reverse engineer, decompile, or otherwise attempt to extract the source code of the software or any part thereof; (n)
has not parsed yet. --> Platform — Deep Origin | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Start a trial → Out-licensing Asset Co-Development Sele
has not parsed yet. --> AI-Powered Drug Discovery Platform | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Start a trial → Out-licensing Asset Co-Deve … ty years of peer-reviewed research in molecular physics underpins the models we apply to pharma programs. LinkedIn → Learn about Deep Origin Latest Resources Insights from our team on drug discovery, computational chemistry, and scientific innovation. View all resources Blog Post Finding Promising Molecules and Biological Background With Balto Read article Company News Can AI Shrink the Drug Development Timelines for Endometriosis? Company News We Built a 98% Accurate Fu
Deep Origin Appoints Shivani Puri as First Chief People Officer | Deep Origin posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, y
Argenta Hosts 23rd VICH GCP Workshop in Munich | Argenta posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’ … "Head", and "Hands", has provided a roadmap for my advocacy work. I am eager to apply these strategies in Phase 2 to ensure that our medicines and our future remain protected. Thank you to the speakers and organizers, The Trinity Challenge VoiceVigil Vet Konect for an impactful start to this journey. #AMR #OneHealth #VoiceVigil #PublicHealth #VeterinaryMedicine #Leadership #TheTrinityChallenge #VetKonect 6 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a … s to surface during examination, where patent offices assess whether the patent application, as filed, provides sufficient support for the scope being claimed. The challenge is striking the right balance between claim ambition and the technical justification that can be reasonably derived from the disclosure at the time of filing. 🛠️ Here are three practical suggestions to manage that balance effectively: ➡️ It may help to check the examples included are sufficiently represe … e). ➡️ It may help to reflect breadth across multiple claim layers, so that the application does not depend on a single all-or-nothing position if that breadth is later questioned. #PharmaIP #AnimalHealthIP #PatentDrafting #PatentStrategy #SecernaLLP 7 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Zoetis 629,433 followers 1mo Report this post April was an eventful month across Zoetis, as teams around the world made time to connect, celebrate pr
Exhibitor Profile - PMWC Precision Medicine World Conference Chat with us , powered by LiveChat Skip to content Chats Contact Speakers Agenda Tickets Menu FULL MENU FULL MENU Register here Rates by JUL. 2 Register here PMWC, Jan 25-27, 2023 PMWC - Silicon valley, ca January 27-29, 2027 Past Event PMWC, Feb 5-7, 2025 PMWC - Silicon valley, ca January 27-29, 2027 Attend Program Schedule Sessions Honorees Speakers Company Competition Showcases Travel Venue Sightseeing Reduced Rates Hotel Flights Exhibits + Map Login / My Account Participate REGISTER TO EXHIBIT Prospectus Attendee Breakdown Apply … ogin / My Account Participate Register to Exhibit Prospectus Attendee Breakdown Apply to speak Sponsorship Inquiry GET UPDATES ABOUT Mission Testimonial Past Conferences Past Honorees Past Speakers FAQ CONTACT US Menu agenda speakers exhibits Contact us agenda speakers exhibits Contact us BUY TICKETS SAVE $1351 BY JUL. 2 Menu Item #1 Item #1 PMWC - Silicon valley, ca Jan. 27-29, 2027 Pittsburgh, pa sep. 23-24 PMWC - Silicon valley, ca Jan. 27-29, 2027 Register Here Rates by J … tend Program Speakers Travel Exhibits + Map Main Program View your save program Award Reception Speaker gallery Select part speakers Exhibit gallery Part conferences Participate Register to Exhibit Apply to speak Sponsorship Inquiry ABOUT Login / My Account CONTACT US Get Updates Pittsburgh, pa sep. 23-24 Register Here Rates by Attend Program Travel Reduced Rates Exhibits + Map Main Program View your save program Award Reception Paticipate Register to Exibit Apply to speak Sp … nomix Labs Alphaexpeditions Alpine Alquest Therapeutics ALS Emergency Treatment Fund Alta Bates Summit Comprehensive Cancer Center Alta Devices AltaQ Altered Egos Comics AltheaDx Althia Altiora Altis Biosystems, LLC Altoida Inc Altos Labs AltruBio Altum Medical Alum Alumot – sprint Aluna Health Alva10 Alveo Technologies Alverno Laboratories AlwaysRx Alykomed Global Solutions LLC Alykomedglobal Alzheimer’s X Alzheon AMA Ama-Assn Amaro Therapeutics Amazon Amber Health Amb … Y Ancestry Anderson Cancer Center Andreessen Horowitz Andrew Andy Strouse Angel Fund Angel Investor ANGLE Biosciences ANGLE Europe Ltd. ANGLE, plc Angleplc Angstrom Bio Angular Medicine Anima AnjaGen Consulting Anl Annai Systems, Inc Annexon Biosciences Annexon Inc Annexonbio Anocca Ansun Biopharma Antenna Anthem Anthony Pastena, M.D. ,P.C Anthos
Fyr - PMWC Precision Medicine World Conference Chat with us , powered by LiveChat Skip to content Chats Contact Speakers Agenda Tickets Menu FULL MENU FULL MENU Register here Rates by JUL. 2 Register here PMWC, Jan 25-27, 2023 PMWC - Silicon valley, ca January 27-29, 2027 Past Event PMWC, Feb 5-7, 2025 PMWC - Silicon valley, ca January 27-29, 2027 Attend Program Schedule Sessions Honorees Speakers Company Competition Showcases Travel Venue Sightseeing Reduced Rates Hotel Flights Exhibits + Map Login / My Account Participate REGISTER TO EXHIBIT Prospectus Attendee Breakdown Apply to speak Spons … ogin / My Account Participate Register to Exhibit Prospectus Attendee Breakdown Apply to speak Sponsorship Inquiry GET UPDATES ABOUT Mission Testimonial Past Conferences Past Honorees Past Speakers FAQ CONTACT US Menu agenda speakers exhibits Contact us agenda speakers exhibits Contact us BUY TICKETS SAVE $1351 BY JUL. 2 Menu Item #1 Item #1 PMWC - Silicon valley, ca Jan. 27-29, 2027 Pittsburgh, pa sep. 23-24 PMWC - Silicon valley, ca Jan. 27-29, 2027 Register Here Rates by J … tend Program Speakers Travel Exhibits + Map Main Program View your save program Award Reception Speaker gallery Select part speakers Exhibit gallery Part conferences Participate Register to Exhibit Apply to speak Sponsorship Inquiry ABOUT Login / My Account CONTACT US Get Updates Pittsburgh, pa sep. 23-24 Register Here Rates by Attend Program Travel Reduced Rates Exhibits + Map Main Program View your save program Award Reception Paticipate Register to Exibit Apply to speak Sp … nomix Labs Alphaexpeditions Alpine Alquest Therapeutics ALS Emergency Treatment Fund Alta Bates Summit Comprehensive Cancer Center Alta Devices AltaQ Altered Egos Comics AltheaDx Althia Altiora Altis Biosystems, LLC Altoida Inc Altos Labs AltruBio Altum Medical Alum Alumot – sprint Aluna Health Alva10 Alveo Technologies Alverno Laboratories AlwaysRx Alykomed Global Solutions LLC Alykomedglobal Alzheimer’s X Alzheon AMA Ama-Assn Amaro Therapeutics Amazon Amber Health Amb … Y Ancestry Anderson Cancer Center Andreessen Horowitz Andrew Andy Strouse Angel Fund Angel Investor ANGLE Biosciences ANGLE Europe Ltd. ANGLE, plc Angleplc Angstrom Bio Angular Medicine Anima AnjaGen Consulting Anl Annai Systems, Inc Annexon Biosciences Annexon Inc Annexonbio Anocca Ansun Biopharma Antenna Anthem Anthony Pastena, M.D. ,P.C Anthos
List of bankrupt, sold, merged, or otherwise defunct biotech, pharma & medical device companies About Directory Promoted Listings Purchase Data Drug Pipelines Data Licensing Weekly Update Newsletter Contact Bankrupt, Merged, Sold, Renamed or Otherwise Defunct Biotech Companies 10BioSystems Website Gone, Apr 2016 10xBio One guy doesn't seem serious Aug 2025; Filings late Mar 2025; Residential address, Jul 2022 - Nov 2023 121 Bio Gone mid 2016 149 Medical Shut down Dec 2022 14M Genomics Shut down, Feb 2016 159 Solutions Acquired by IQVIA, May 2018 … b 2024 to become 3PBIOVIAN 3PrimeDx No website Nov 2018 - Mar 2020; SBIR grant 3PrimiR Funded in 2009, presumed defunct 3Scan Merged with Transcriptic, to become Strateos, Jun 2019 4-Antibody Bought by Agenus, Jan 2014, $10M 454 Life Sciences Bought by Roche, Mar 2007, $454M 480 Biomedical Renamed Lyra Therapeutics, Sep 2018 490 BioTech Website down Feb 2025 - Jul 2025 4C Biotech Acquired by Henogen, Jul 2003 4Cli … Scientific Subsumed into parent Biopraxis No website no info. 1996 SBIR grant. Seems to be an umbrella group Biopredic Renamed Wepredic, Mar 2022 BioProcess Technology Consultants Acquired by BDO USA, Apr 2019 Bioprocessing Inc. Bought by Bio-Rad Bioprospecting Renamed Soricimed Biopharma, 2010 Biopta Acquired by ReproCELL, combined with Reinnervate to become ReproCELL Europe, Jul 2016 BiOptix Sold for cryptocurrency ticker us … Acquired by Concentra Biosciences, Aug 2025 Carigent Therapeutics Had a grant in 2008. No info for a long time Carina Biotech Website down Jan 2026 - May 2026 Carisma Therapeutics Winding down Jan 2026 Carlina Technologies Website down Dec 2020 - Feb 2021 Carma Therapeutics Renamed Carisma Therapeutics, 2018 Carmel Biosciences Acquired by Nutriband, Sep 2018, $2.7M Carmell Corporation Merged with Axolotl Biologix, Aug 2023; fk … Aug 2021 - Jul 2024 CERAMIDE THERAPEUTICS No info. Jun 2015. $1.5M SBIR grant 2011 Cerebain Biotech Website down Dec 2022 - Apr 2023 Cerebral Therapeutics Website down Dec 2024; LI page gone Jul 2024 Cerebral Therapeutics Website down Jan 2025 - Jun 2025 Cerebroscience One employee, website gone Cerebrot
Attendee List | Drug Discovery Chemistry | April 13-16, 2026 About About Us FAQ Drug Discovery Chemistry Europe Agenda Programs Search Agenda Plenary Sessions Speaker Biographies Short Courses Training Seminar Top Pharma Breakout Discussions Attendee List Testimonials On-site Networking  Archives Sponsor/Exhibitor Attendee Demographics + Event Features Sponsorship Opportunities Current Sponsors Sponsor Prospectus Current Exhibitors/Floorplan 2027 Re-sign Floorplan Exhibit Services/Schedule Lead Generation Opportunities Sponsor & Exhibitor Portal Media Partners Best of Show Awards Down
Scientists Leverage Sankey Plots for Protein Optimization with proteinML | Stef van Grieken posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join
Investor News - Ginkgo Bioworks Skip to main content Overview Why Invest News Stock Info SEC Filings SEC Filings Quarterly Reports Annual Reports Governance Executive Management Board of Directors Committee Composition Governance Documents Resources Investor FAQs Analyst Coverage Contact Email Alerts Skip to main content --> Menu Covid-19 --> Our Platform Our Work --> Careers --> Press About Blog Investors Contact Us Investor News Overview Why Invest News Stock Info SEC Filings SEC Filings Quarterly Reports Annual Reports Governance Executive Management Board of Directors Committee Composition
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
#nucleate #nucleatesummit2025 #biotech #lifesciences #academicentrepreneurship #innovation #leadership #community #mentorship #communication | Dante Dennis Acenas, II | 26 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept
American Chemical Society Skip to main content Garegin Papoian Deep Origin Inc Appearances × Evaluation Close Print Submit
#venturecapital #careeradvice #startups #building #realtalk | Milad Alucozai | 21 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Linked … heets work. I watched a Stanford CS grad spend two years as an analyst at a top fund. Know what she learned? How to take notes in partner meetings where she couldn't speak. How to analyze markets she'd never sold into. How to evaluate founders when she'd never missed payroll. She's now building her own startup. Wishes she'd started two years earlier. 𝗧𝗵𝗲 𝗿𝗲𝘃𝗼𝗹𝘃𝗶𝗻𝗴 𝗱𝗼𝗼𝗿 𝗶𝘀 𝗿𝗲𝗮𝗹: Most funds cycle through analysts like seasonal interns. Why? Because the pat … nal interns. Why? Because the path from analyst to partner is rare. Look at any fund's team page. Count the partners who started as analysts there. If you want to break into venture, here's what actually works: 𝗕𝘂𝗶𝗹𝗱 𝘀𝗼𝗺𝗲𝘁𝗵𝗶𝗻𝗴 𝗳𝗶𝗿𝘀𝘁. Join a startup. Any startup. Feel the chaos of finding product-market fit. Experience the panic of runway running out. Learn what founders actually need. Or better yet, become a founder. Even if you fail. Especially if you fail … ts spending their days updating CRM systems at VC funds, the problem is said VC fund, or the analyst themselves. Sure you're likely the most junior person on the team and need to execute, but there's nothing stopping you from pushing to do the work of an Associate / Principal by bringing deals to the table, evaluating opps, sharing your viewpoints, and pushing for healthy debate. If a fund prevents you from doing this, then agreed, get out. But if not, there's few other oppor … s also CRM filling and e-mail And Pressure culture I don’t Know. … If one is at fund early on and sure provides value by doing CRM stuff he can still observe and learn from the full circle. Rome was not build in a day but at least it was Rome Working for a chaotic startup often for free vs stable Sallary at reputable fund that can be put on resum
Attendee List About About the Event Attendee List Social Media Get Involved Online Learning & Podcasts Media Gallery Testimonials Key Contacts FAQ Agenda Search Agenda Event-at-a-Glance Conference Tracks Symposia Workshops FAIR Data Hackathon Plenary Keynotes Interactive Discussions Intelligence Briefs Speaker Biographies Brochures Networking Venture/Partner Event Sponsorship Attendee Demographics + Features Sponsorship Opportunities Current Sponsors Sponsorship Prospectus Current Exhibitors/Floorplan Re-sign Floorplan Exhibit Services / Schedule Lead Gen Opportunities FAQs Innovation Show … wcase Awards Innovative Practices Awards Best of Show Awards Emerging Innovator Award Travel Press Newsroom Media Partners Press Pass Podcast Posters Poster Information Poster Titles Register Individual Pricing Group Pricing On-Demand Pricing Exhibit Hall & Keynote Pass 2026 Attendee List Join the growing list of your peers for 22nd Annual Bio-IT World Conference & Expo (Partial List Only) --> - Attending in person - Attending virtually Compan
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Weekly Tech+Bio Highlights #74: Big Pharma AI Tie-Ups Lean Toward Real-World Data Where Tech Meets Bio Subscribe Sign in Weekly Highlights Weekly Tech+Bio Highlights #74: Big Pharma AI Tie-Ups Lean Toward Real-World Data Quick run of pharma-AI collaborations, a new startup based on Google's cell sentence tech, and $100 genome sequencing from San Diego BiopharmaTrend and Roman Kasianov Feb 23, 2026 ∙ Paid 20 2 2 Share This past week’s pattern was a cluster of big-pharma and large healthcare collaborations that pull AI closer to multimodal biological and clinical data, and closer to lab and deve
Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety | FirstWord HEALTHTECH You need to enable JavaScript to run this app. Loading...
AI Hype and Reality - Three scientists go on a hike in Deep Origin - OncoDaily Calculators Oncologists OncoCalendar News Feed OncoDaily Pulse OncoGrants OncoDaily TV NewsLetter Voices Not To Miss FDA Approvals New Paper Alert OncoDaily 100 Community OncoDaily Magazine Career Updates Oncology Drugs Dialogues Stories Celebrities and Cancer Immune Oncology Breast Oncology Gastrointestinal Oncology Lung Oncology Hematology Radiotherapy Cancer Types Science Trial Updates ASCO ESMO ESO MASCC Cancer Center Near Me Oncologist Near Me OncoDaily Party 2025 Childhood Cancer Health Policy Hall of Fame Onc … Blog Posts BIGR Global Cancer Movement History Oncolibrary OncoThon 2025 Yvonne Award 2025 Jun / 2026 June 2026 M T W T F S S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 « May OncoDaily IO OncoDaily GI Hemostasis Today Fertility News Voices Not To Miss FDA Approvals New Paper Alert OncoDaily 100 Community OncoDaily Magazine Career Updates Oncology Drugs Dialogues Stories News Feed OncoDaily Pulse OncoGrants OncoD
has not parsed yet. --> Accelerating Drug Discovery with Physics-Informed Machine Learning | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Start a trial &r
has not parsed yet. --> Discovering Novel Synthetic Lethal Pairs With Large Scale Cellular Simulations | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Star
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Abstract: NEW PB- AND CU-ISOTOPE DATA SUPPORTING A DEEP ORIGIN OF METALLIC NANOPARTICLES IN BONANZA EPITHERMAL ORES OF THE NORTHERN GREAT BASIN, NEVADA-IDAHO (2012 GSA Annual Meeting in Charlotte) The Geological Society of America 2012 GSA Annual Meeting in Charlotte Charlotte, North Carolina, USA About Conference Expo Sponsors Lodging/Travel Registration Media Center --> Start Grid View Author Index View Uploaded Presentations Meeting Information Paper No. 3 Presentation Time: 8:40 AM NEW PB- AND CU-ISOTOPE DATA SUPPORTING A DEEP ORIGIN OF METALLIC NANOPARTICLES IN BONANZA EPITHERMAL ORES OF
Deep Origin Collaborates with ARPA-H on Virtual Human System for Faster Drug Development | Natalie Ma, PhD posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking C … 6mo Edited Report this post ARTIDIS is pleased to announce the 2026 NanoArgovia grant recipient in collaboration with Prof. Dr. Laura Suter-Dick and Prof. Dr. Per Magnus Kristiansen together with ARTIDIS Lead Scientist of in Vitro Nanotechnology Application Dr. Reinier Oropesa-Nuñez and CMO Dr. Marko Loparic . As part of the NanoDiLi project, we will leverage ARTIDIS ’ AFM-based technology to benchmark the mechanical signatures of liver microtissues against established bioche
Deep Origin sponsors Computational Medicinal Chemistry School | Natalie Ma, PhD posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in,
Announcing Deep Origin as a sponsor of ARDD 2025 | Aging Research & Drug Discovery Meeting LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Li … Finding New Hope for Devastating Brain Diseases | 2026 BioMarin Genetic Pioneer Award | 2025 CLS Pantheon Award Winning AI Platform | NSF and NIA Funded | H-index 46 8mo Edited 🚨 Voting is now open! 🚨 We’re honored that BrainStorm Therapeutics, Inc. has been nominated for the California Life Sciences (CLS) Pantheon Awards in the AI Catalyst for Health category. 🏆🌟 Our nomination reflects our mission to transform drug discovery for complex brain diseases by integrating AI
Copy of ARDD 2026 Main Past events ARDD 2025 ARDD 2024 XPRIZE Healthspan Team Summit 2024 ARDD 2023 ARDD 2022 About Speakers Speakers 2026 Speakers 2025 Speakers 2024 Speakers 2023 Speakers 2022 Program Main Track Longevity Medicine Track Emerging Science & Technologies Workshop Physics in Aging Biology Startup Pitch Replacement in Aging Workshop Molecular Nutrition Workshop ARDD Tracks Sponsorship Sponsorship Brochure Sponsors 2025 Sponsors 2024 Sponsors 2023 Sponsors 2022 Media Scam Warning Photos Videos Media Kit Photos 2025 Photos 2024 Photos 2023 Photos 2022 Video … uotes Really enjoyed the breadth of talks and discussions. Michael Levitt Nobel Prize in Chemistry 2013 Stanford Phenomenal conference in the Rejuvenation Field. Steve Horvath Principal Investigator Altos Lab Where one can learn about aging scientifically, clinically and in real life. Xingli Wang Fosun Global Partner Fosun Pharma The ARDD event pioneers the future of healthy aging, driving breakthroughs in longevity research while opening a new era of cosmetic innovation Luc … ming and hearing about transformative technologies in the workshops. And Alex’s proposal to Dominika most memorable! Adam Antebi Max Planck Institute for BIology of Ageing, Cologne, Germany We are at a pivotal moment. The stars have aligned to make real progress in understanding aging and ultimately extending longevity. I found ARDD to be the nexus where diverse perspectives converge, accelerating this progress. Albert-László Barabási Northeastern University Attending for the
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Machine Learning Researcher - Deep Origin | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Deep Origin Jobs Machine Learning Researcher Deep Origin Machine Learning Researcher Sorry, this job was removed at 06:17 p.m. (UTC) on Wednesday, Mar 04, 2026 Be an Early Applicant Yerevan, ARM In-Office Cloud • Database • Analytics • Biotech The Role Can machine learning help solve diseases? Deep Origin is a biotechnology company accelerating drug discovery through machine learning and simulation. Our plat … all jobs at Deep Origin View Deep Origin Profile Report Job Continue Log In to apply Sign up to apply Apply Instructions By clicking Apply Now you agree to share your profile information with the hiring company. Sign up now Access later Create Free Account Already have an account? Log In Please log in or sign up to report this job. Create Free Account Already have an account? Log In Companies Jobs Tracker Articles More Join Log In Tech Jobs Companies Articles Remote Best Pla
Such a pleasure and honor to support Nucleate and the 2025 Summit! Come check out our booth if you are in town and we will not only give you free access to Balto - the first drug discovery AI… | Deep Origin LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time
Scientia Ventures Scientia Ventures Scientia About Portfolio People Podcasts News Portfolio People Podcasts News About Episode Summary If you believe that computation will help companies get better at developing new drugs, then what specific kind of computation and software should you invest in? Quantum chemistry simulations? Molecular dynamics simulations? Generative AI models? Harry's guests this week, Garegin Papaoian and Michael Antonov, lead a company called Deep Origin that's taking an all-of-the-above approach. The company’s philosophy is that physics-based modeling by itself
has not parsed yet. --> Simulating Life & Accelerating Discovery: Deep Origin's Biotech Vision | Michael Antonov (Part 4/4) | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capabil
"Deep Origin CEO on digital tools for biotech" | Excedr posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to
Why Deep Origin Is Betting on … - The Harry Glorikian Show - Apple Podcasts Search Home New Top Charts Search February 27, 2024 51 min Why Deep Origin Is Betting on Both Physics and AI for Drug Discovery The Harry Glorikian Show Play Investors and companies in the life science industry have been betting a lot of money over the last few years on a single idea: that computation will help us get a lot better at developing new drugs. But the word “computation” covers a pretty broad range of techniques. And the reason that there are dozens if not hundreds of computational drug discovery startups po
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Simulating Life & Accelerating Discovery: Deep Origin’s Biotech Vision | Michael Antonov (Part 4/4) Episodes Guests About Host Contact Simulating Life & Accelerating Discovery: Deep Origin’s Biotech Vision | Michael Antonov (Part 4/4) Listen or watch on your favorite platform: Show Notes "If you really want to understand biology, you need to be able to represent it in the computer. If you can’t model it, you can’t really predict its behavior” In this episode of The Biotech Startups Podcast, Michael Antonov, Co-Founder of Oculus and Founder & CEO of Deep Origin, returns for the … did that come to be? Gemma - 00:01:24: So Formic VC was the kind of name of our fund. And we started in basically 2019 and operated for a few years. We're still like legal entity exists and I'll still occasionally invest. But now I'm very just focused on the company on Deep Origin. So Formic Labs kind of came out with this idea of how do we build simulations for life? So as I was starting to invest, I looked at all these tools. And it seemed to me, I actually w … GPU, right? So there's not a very easy universal way to write a scientific application. So it can run by anyone, anywhere. And it will keep running if somebody just accesses it. So that's part of a reason. And then there is a number of companies which are coming in, which are trying to solve this for businesses. And so you can look like there is good work, let's say, Benchling has done on infrastructure. There's a number of other startups. The challenge I … o control it. So there's not like an open ecosystem where you can write an application which runs anywhere, which maybe you can even make money for, which does scientific stuff. That is part of a ecosystem challenge. Another challenge is that if you are in investing, and you're investing in biotech startups, It's actually hard to raise money for tools. So it's more, there's a typical way, if you have an idea for something and you have one therapeutic,
Why Deep Origin Is Betting on … ‑ The Harry Glorikian Show ‑ Apple Podcasts Rechercher Accueil Nouveautés Classements Rechercher 27 février 2024 51 min Why Deep Origin Is Betting on Both Physics and AI for Drug Discovery The Harry Glorikian Show Lire Investors and companies in the life science industry have been betting a lot of money over the last few years on a single idea: that computation will help us get a lot better at developing new drugs. But the word “computation” covers a pretty broad range of techniques. And the reason that there are dozens if not hundreds of computational drug disc
Deep Origin's Garegin Papoian on Biotech and AI Breakthroughs | Henk Campher posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in
Tim Foley Joins Deep Origin as Chief Commercial Officer | Deep Origin | Tim Foley | 13 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to L
Head of Product - Deep Origin | Built In San Francisco San Francisco Global Tech Hub BuiltIn.com is the global destination for tech professionals. builtin.com Popular Tech Hubs United States Austin Boston Chicago Colorado Los Angeles New York City Seattle San Francisco Australia Sydney Melbourne Canada Calgary Montreal Ottawa Quebec Toronto Vancouver India Bengaluru Chennai Delhi Hyderabad Kolkata Mumbai Pune Ireland Dublin Singapore Singapore United Kingdom London Cambridge Manchester Birmingham Bristol Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs J … or AI Safety; California Institute for Regenerative Medicine Continue Log In to apply Sign up to apply Apply Instructions By clicking Apply Now you agree to share your profile information with the hiring company. Sign up now Access later Create Free Account Already have an account? Log In Please log in or sign up to report this job. Create Free Account Already have an account? Log In Companies Jobs Tracker Articles More Join Log In Tech Jobs Companies Articles Remote Salaries
Deep Origin - AI Drug Discovery & Development Summit Skip To Main Content October 27-29, 2026 Boston Marriott Copley Place, Boston BOOK NOW (opens in a new tab) Home Show submenu for: Home Stages Show submenu for: Stages Discovery Biology Discovery Chemistry Data Management & Data Science Stage HPC & AI Infrastructure Clinical Trials TechOps Agenda Speakers Show submenu for: Speakers 2026 Line-Up Discovery Biology Discovery Chemistry Data Management & Data Science AI Infrastructure & HPC Clinical Trials TechOp Innovation Sponsors Show submenu for: Sponsors 2026 Sponsors Sponsor Opportunities S
Ginkgo Bioworks joins ARPA-H CATALYST project on drug safety AI | DNA Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto … decline, GAAP net loss, but guidance reaffirmed for 2025. Nov 03 BARDA project award Positive -1.5% BARDA BioMaP agreement up to $22.2M for mAb biomanufacturing. Oct 31 Strategic partnership Positive +8.2% Extension of multi-year Bayer partnership in agricultural biologicals. Pattern Detected Positive partnership and government contract news has often aligned with modest to strong gains, while one BARDA award saw a negative reaction despite positive fundamentals. Recent Comp
Deep Origin joins Nucleate Summit as Silver Sponsor | Nucleate posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Lin
Deep Origin - AI Drug Discovery & Development Summit Skip To Main Content October 27-29, 2026 Boston Marriott Copley Place, Boston BOOK NOW (opens in a new tab) Home Show submenu for: Home Stages Show submenu for: Stages Discovery Biology Discovery Chemistry Data Management & Data Science Stage HPC & AI Infrastructure Clinical Trials TechOps Agenda Speakers Show submenu for: Speakers 2026 Line-Up Discovery Biology Discovery Chemistry Data Management & Data Science AI Infrastructure & HPC Clinical Trials TechOp Innovation Sponsors Show submenu for: Sponsors 2026 Sponsors Sponsor Opportunities S
Deep Origin Congratulates Isomorphic Labs on Catching Up | FirstWord HEALTHTECH You need to enable JavaScript to run this app. Loading...
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
has not parsed yet. --> JPM ‘25 From the Trenches: AI in Biotech Gets Tactical | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Start a trial → Out-lic … research, given the federal government’s announcement of a pause in all federal grant funding ( here’s coverage from C&EN ). Though that memo has since been rescinded, we realize a lot of folks are intensely uncertain about what will happen. If you use our tools and need accommodations because of the situation, please feel free to reach out to us at here . JPM ‘25 catches us at a time of greater flux than any since COVID- The name of the game over the last week wasn’t AI … y, Amgen needed about 26 weeks from database lock to filing a Biologics License Application (BLA). Automation has significantly shortened this timeframe, including cutting the report-generation phase from 6 weeks to just 2-3 days. Today, the full BLA process takes 12 weeks, with ongoing efforts to reduce this further to 8 weeks by mid-next year. Post-Approval CMC Changes: Securing global approvals for post-approval Chemistry, Manufacturing, and Controls (CMC) changes once req
has not parsed yet. --> Deep Origin and BiosimAI join forces in merger to accelerate R&D | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Start a trial
has not parsed yet. --> DO Studio — Drug Discovery Without the Silicon Moat | Deep Origin | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Start a trial &ra … against the same project data — no exports, no copy-paste. The core innovation Submit a job. The platform handles everything. A researcher submits a job and Studio orchestrates the rest end-to-end — without leaving the platform, touching a file, or configuring a single parameter. 1 Submit a job from the browser Drop in a protein and ligands. Pick the workflow. No AWS console, no SLURM script, no install. 2 Compute scales automatically An automated AWS backend spins up exactl
Tim Foley Joins Deep Origin as Chief Commercial Officer | Deep Origin posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree … eek. Blackstone simultaneously announced the largest-ever private life sciences fund close at $6.3B — a strong signal of sustained institutional conviction. 🔄 Crossover & Pre-IPO Activity: Kailera Therapeutics — which has raised $1B in venture funding since 2024 for its GLP-1/metabolic disease programs — filed for IPO on April 1, 2026, joining an early 2026 cohort with a median raise of $287.5M. The metabolic disease and obesity space continues to attract premium public … ct premium public market valuations. 🏦 VC Activity: Beyond Blackstone's record fund, March 2026 saw strong deal flow in oncology, ADCs, and AI-powered drug discovery. Investors are increasingly requiring clinical-stage proof points alongside platform narratives — the era of purely platform-based valuations is narrowing. 🎓 Academic → Industry Movement: NIH budget uncertainty (a proposed 40% cut under the current administration) is prompting senior academic scientists — PIs, … a tells a clear story: $12B+ in acquisitions, the largest private life sciences fund ever raised, and the first oral GLP-1 reaching market. This is a sector in active, confident motion — and the organizations with the right leadership in place will be best positioned to capitalize on what comes next. #LifeSciences #Biotech #MarketReport #VentureCapital #Pharma #LumaBioPartners #WeeklyRoundup Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Joseph … eek. Blackstone simultaneously announced the largest-ever private life sciences fund close at $6.3B — a strong signal of sustained institutional conviction. 🔄 Crossover & Pre-IPO Activity: Kailera Therapeutics — which has raised $1B in venture funding since 2024 for its GLP-1/metabolic disease programs — filed for IPO on April 1, 2026, joini
Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Ph … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
has not parsed yet. --> Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free t
has not parsed yet. --> AI-Powered Drug Discovery Platform | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Start a trial → Out-licensing Asset Co-Deve … ty years of peer-reviewed research in molecular physics underpins the models we apply to pharma programs. LinkedIn → Learn about Deep Origin Latest Resources Insights from our team on drug discovery, computational chemistry, and scientific innovation. View all resources Blog Post Finding Promising Molecules and Biological Background With Balto Read article Company News Can AI Shrink the Drug Development Timelines for Endometriosis? Company News We Built a 98% Accurate Fu
Lead Automation QA Engineer - Deep Origin | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Deep Origin Jobs Lead Automation QA Engineer Deep Origin Lead Automation QA Engineer Sorry, this job was removed at 02:17 p.m. (UTC) on Thursday, Sep 25, 2025 Be an Early Applicant 3 Locations Remote Cloud • Database • Analytics • Biotech The Role Led by Michael Antonov, a co-founder of Oculus, and well-funded by Formic Ventures, Deep Origin is poised to reinvent the way scientists work and life science inno … rvices • Cryptocurrency • Web3 Remote 17 Locations 2900 Employees Apply Digital Quality Assurance Automation Engineer Information Technology Remote or Hybrid 12 Locations 449 Employees Mastercard Director, Product Marketing Blockchain • Fintech • Payments • Consulting • Cryptocurrency • Cybersecurity • Quantum Computing Remote or Hybrid São Paulo, BRA 38800 Employees Get Personalized Job Insights. Our AI-powered fit … all jobs at Deep Origin View Deep Origin Profile Report Job Continue Log In to apply Sign up to apply Apply Instructions By clicking Apply Now you agree to share your profile information with the hiring company. Sign up now Access later Create Free Account Already have an account? Log In Please log in or sign up to report this job. Create Free Account Already have an account? Log In Companies Jobs Tracker Articles More Join Log In Tech Jobs Companies Articles Remote Best Pla
How Deep Origin's CEO innovates in drug discovery | Deep Origin posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree t … CSM-1B, under an Apache 2.0 license, signals a commitment to broader commercial application and innovation within the AI landscape. This development is poised to significantly impact the wearables and AI sectors. #AI , #SmartGlasses , #ConversationalAI , #TechInvestment Sesame AI: Voice-Powered Future https://techbriefly.com 6 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Andreas Riegler 8mo Report this post AR and VR were once seen as experime … AI is making AR and VR systems more intelligent, more responsive, and easier to apply in real-world environments. The broader trend is clear: AR/VR is no longer a speculative bet. That changes the lens for both founders and investors. Instead of asking “What can we build with AR/VR?”, the better question is: “Where does this technology naturally integrate to unlock measurable value?” #VentureCapital #AI #DeepTech #Startups Follow us at APEX Ventures and subscribe to our newsl … AI is making AR and VR systems more intelligent, more responsive, and easier to apply in real-world environments. The broader trend is clear: AR/VR is no longer a speculative bet. That changes the lens for both founders and investors. Instead of asking “What can we build with AR/VR?”, the better question is: “Where does this technology naturally integrate to unlock measurable value?” #VentureCapital #AI #DeepTech #Startups Follow us at APEX Ventures and subscribe to our newsl
has not parsed yet. --> Why Deep Origin Is Betting on Both Physics and AI for Drug Discovery (EP 132) | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Start
has not parsed yet. --> Simulating Life with AI: A New Era in Biology with Michael Antonov & Natalie Ma from Deep Origin | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Fr
Michael Antonov: on founding Oculus VR, Deep Origin, and the future of biotech | Deep Origin LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Link
The Borrowed Computer That Built Oculus - An Unlikely Biotech Journey | Michael Antonov (Part 1/4) Episodes Guests About Host Contact The Borrowed Computer That Built Oculus - An Unlikely Biotech Journey | Michael Antonov (Part 1/4) Listen or watch on your favorite platform: Show Notes “One cell is way more complicated than a spaceship.” In this episode of The Biotech Startups Podcast, we sit down with Michael Antonov, Co-Founder of Oculus and Founder & CEO of Deep Origin, to explore the early experiences that shaped his path from software to biotech. Raised in post-Soviet Russia by a fami … ve, you know, three week project, which I would do last day in like five hours. Submit. So they had to like the digital system. You can submit before 12 a.m.. So it's literally submitted like 11:50. I would get it done in like three or four hours because the program, I didn't do any. Like I basically could program whatever I wanted. But some of the more like when they told, gave me an exam and say, prove this thing. I would come up with two things. It's either
has not parsed yet. --> Michael Antonov - Co-Founder and CEO | Deep Origin Deep Origin awarded $31.7M ARPA-H contract to replace animal testing with in-silico models. Learn more Validated Assets Partnerships Research collaboration Discovery Partnership Full-stack access to our model suite applied to your target. Multi-year engagement, program milestones, optional IP co-ownership. 40 slots · 2 filled → SaaS Platform Access Subscription access to Balto AI and DO Patent for teams with existing computational capability. Free trial on-ramp. Start a trial → Out-licensing Asset Co-De